Verrica Pharmaceuticals Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 10.17 million compared to USD 11.78 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.43 a year ago. Diluted loss per share from continuing operations was USD 0.37 compared to USD 0.43 a year ago.
For the six months, net loss was USD 18.64 million compared to USD 12.71 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.46 a year ago. Diluted loss per share from continuing operations was USD 0.68 compared to USD 0.46 a year ago.